TY  - GEN
AU  - Robert,Caroline
AU  - Karaszewska,Boguslawa
AU  - Schachter,Jacob
AU  - Rutkowski,Piotr
AU  - Mackiewicz,Andrzej
AU  - Stroiakovski,Daniil
AU  - Lichinitser,Michael
AU  - Dummer,Reinhard
AU  - Grange,Florent
AU  - Mortier,Laurent
AU  - Chiarion-Sileni,Vanna
AU  - Drucis,Kamil
AU  - Krajsova,Ivana
AU  - Hauschild,Axel
AU  - Lorigan,Paul
AU  - Wolter,Pascal
AU  - Long,Georgina V
AU  - Flaherty,Keith
AU  - Nathan,Paul
AU  - Ribas,Antoni
AU  - Martin,Anne-Marie
AU  - Sun,Peng
AU  - Crist,Wendy
AU  - Legos,Jeff
AU  - Rubin,Stephen D
AU  - Little,Shonda M
AU  - Schadendorf,Dirk
TI  - Improved overall survival in melanoma with combined dabrafenib and trametinib
SN  - 1533-4406
PY  - 2015///0107
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - administration & dosage
KW  - Indoles
KW  - Intention to Treat Analysis
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Mitogen-Activated Protein Kinase Kinases
KW  - antagonists & inhibitors
KW  - Mutation
KW  - Oximes
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins B-raf
KW  - Pyridones
KW  - Pyrimidinones
KW  - Skin Neoplasms
KW  - Sulfonamides
KW  - Survival Analysis
KW  - Vemurafenib
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1056/NEJMoa1412690
ER  -